{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:55:19Z","timestamp":1795020919653,"version":"4.10.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sepsis, a dysregulated host response to infection characterized by organ failure, is one of the leading causes of death worldwide. Disbalances of the immune response play an important role in its pathophysiology. Patients may develop simultaneously or concomitantly states of systemic or local hyperinflammation and immunosuppression. Although a variety of effective immunomodulatory treatments are generally available, attempts to inhibit or stimulate the immune system in sepsis have failed so far to improve patients\u2019 outcome. The underlying reason is likely multifaceted including failure to identify responders to a specific immune intervention and the complex pathophysiology of organ dysfunction that is not exclusively caused by immunopathology but also includes dysfunction of the coagulation system, parenchymal organs, and the endothelium. Increasing evidence suggests that stratification of the heterogeneous population of septic patients with consideration of their host response might led to treatments that are more effective. The purpose of this review is to provide an overview of current studies aimed at optimizing the many facets of host response and to discuss future perspectives for precision medicine approaches in sepsis.<\/jats:p>","DOI":"10.1186\/s13054-023-04762-6","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T04:02:34Z","timestamp":1701835354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Targeting the host response in sepsis: current approaches and future evidence"],"prefix":"10.1186","volume":"27","author":[{"given":"Christian","family":"Bode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Wendel-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"10219","key":"4762_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study. The Lancet. 2020;395(10219):200\u201311.","journal-title":"The Lancet"},{"issue":"11","key":"4762_CR2","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","volume":"54","author":"T van der Poll","year":"2021","unstructured":"van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021;54(11):2450\u201364.","journal-title":"Immunity"},{"key":"4762_CR3","doi-asserted-by":"publisher","first-page":"104363","DOI":"10.1016\/j.ebiom.2022.104363","volume":"86","author":"WJ Wiersinga","year":"2022","unstructured":"Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. EBioMedicine. 2022;86:104363.","journal-title":"EBioMedicine"},{"issue":"8","key":"4762_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"18","key":"4762_CR5","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/bloodadvances.2021004453C","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch S, Gill S. The promise and perils of immunotherapy. Blood Adv. 2021;5(18):3709\u201325.","journal-title":"Blood Adv"},{"key":"4762_CR6","doi-asserted-by":"publisher","first-page":"107476","DOI":"10.1016\/j.pharmthera.2020.107476","volume":"208","author":"F Steinhagen","year":"2020","unstructured":"Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis\u2014brake or accelerate? Pharmacol Ther. 2020;208:107476.","journal-title":"Pharmacol Ther"},{"key":"4762_CR7","unstructured":"Death by TNF: a road to inflammation: PubMed [Internet]. [cited 2023 Nov 12]. https:\/\/pubmed.ncbi.nlm.nih.gov\/36380021\/."},{"issue":"12","key":"4762_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","volume":"273","author":"E Abraham","year":"1995","unstructured":"Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273(12):934\u201341.","journal-title":"JAMA"},{"issue":"19","key":"4762_CR9","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jama.1997.03540430043031","volume":"277","author":"E Abraham","year":"1997","unstructured":"Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA. 1997;277(19):1531\u20138.","journal-title":"JAMA"},{"issue":"9107","key":"4762_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","volume":"351","author":"E Abraham","year":"1998","unstructured":"Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 1998;351(9107):929\u201333.","journal-title":"Lancet"},{"issue":"9","key":"4762_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","volume":"24","author":"J Cohen","year":"1996","unstructured":"Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996;24(9):1431\u201340.","journal-title":"Crit Care Med"},{"issue":"26","key":"4762_CR12","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","volume":"334","author":"CJ Fisher","year":"1996","unstructured":"Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334(26):1697\u2013702.","journal-title":"N Engl J Med"},{"issue":"4","key":"4762_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ijcp.12382","volume":"68","author":"S Lv","year":"2014","unstructured":"Lv S, Han M, Yi R, Kwon S, Dai C, Wang R. Anti-TNF-\u03b1 therapy for patients with sepsis: a systematic meta-analysis. Int J Clin Pract. 2014;68(4):520\u20138.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"4762_CR14","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1097\/01.CCM.0000145229.59014.6C","volume":"32","author":"EA Panacek","year":"2004","unstructured":"Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab\u2019)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32(11):2173\u201382.","journal-title":"Crit Care Med"},{"issue":"1","key":"4762_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8\u201327.","journal-title":"Immunol Rev"},{"issue":"7","key":"4762_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25(7):1115\u201324.","journal-title":"Crit Care Med"},{"issue":"23","key":"4762_CR17","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","volume":"271","author":"CJ Fisher","year":"1994","unstructured":"Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271(23):1836\u201343.","journal-title":"JAMA"},{"issue":"1","key":"4762_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/CCM.0000000000002749","volume":"46","author":"NJ Meyer","year":"2018","unstructured":"Meyer NJ, Reilly JP, Anderson BJ, Palakshappa JA, Jones TK, Dunn TG, et al. Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med. 2018;46(1):21\u20138.","journal-title":"Crit Care Med"},{"issue":"2","key":"4762_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275\u201381.","journal-title":"Crit Care Med"},{"issue":"10","key":"4762_CR20","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752\u201360.","journal-title":"Nat Med"},{"key":"4762_CR21","doi-asserted-by":"publisher","first-page":"154360","DOI":"10.1016\/j.jcrc.2023.154360","volume":"78","author":"AH de Nooijer","year":"2023","unstructured":"de Nooijer AH, Pickkers P, Netea MG, Kox M. Inflammatory biomarkers to predict the prognosis of acute bacterial and viral infections. J Crit Care. 2023;78:154360.","journal-title":"J Crit Care"},{"issue":"8","key":"4762_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist"},{"issue":"6","key":"4762_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","volume":"326","author":"M Shankar-Hari","year":"2021","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499\u2013518.","journal-title":"JAMA"},{"issue":"6","key":"4762_CR24","first-page":"CD013881","volume":"6","author":"L Ghosn","year":"2023","unstructured":"Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023;6(6):CD013881.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4762_CR25","doi-asserted-by":"publisher","first-page":"e1004174","DOI":"10.1371\/journal.pmed.1004174","volume":"20","author":"FW Hamilton","year":"2023","unstructured":"Hamilton FW, Thomas M, Arnold D, Palmer T, Moran E, Mentzer AJ, et al. Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: a Mendelian randomisation study. PLoS Med. 2023;20(1):e1004174.","journal-title":"PLoS Med"},{"key":"4762_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I: molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.","journal-title":"Front Immunol"},{"issue":"37","key":"4762_CR27","doi-asserted-by":"publisher","first-page":"e2104347118","DOI":"10.1073\/pnas.2104347118","volume":"118","author":"RS Keshari","year":"2021","unstructured":"Keshari RS, Popescu NI, Silasi R, Regmi G, Lupu C, Simmons JH, et al. Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons. Proc Natl Acad Sci U S A. 2021;118(37):e2104347118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4762_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/blood-2010-02-269746","volume":"116","author":"R Silasi-Mansat","year":"2010","unstructured":"Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116(6):1002\u201310.","journal-title":"Blood"},{"issue":"31","key":"4762_CR29","doi-asserted-by":"publisher","first-page":"E6390","DOI":"10.1073\/pnas.1706818114","volume":"114","author":"RS Keshari","year":"2017","unstructured":"Keshari RS, Silasi R, Popescu NI, Patel MM, Chaaban H, Lupu C, et al. Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc Natl Acad Sci U S A. 2017;114(31):E6390\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"4762_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s13054-015-1129-9","volume":"27","author":"EW Skjeflo","year":"2015","unstructured":"Skjeflo EW, Sagatun C, Dybwik K, Aam S, Urving SH, Nunn MA, et al. Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Crit Care. 2015;27(19):415.","journal-title":"Crit Care"},{"issue":"11","key":"4762_CR31","doi-asserted-by":"publisher","first-page":"e0577","DOI":"10.1097\/CCE.0000000000000577","volume":"3","author":"M Bauer","year":"2021","unstructured":"Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis or septic shock-A randomized, placebo-controlled, double-blind, multicenter, phase IIA trial (SCIENS study). Crit Care Explor. 2021;3(11):e0577.","journal-title":"Crit Care Explor"},{"key":"4762_CR32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3389\/fimmu.2018.01736","volume":"9","author":"N Heming","year":"2018","unstructured":"Heming N, Sivanandamoorthy S, Meng P, Bounab R, Annane D. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736.","journal-title":"Front Immunol"},{"issue":"7","key":"4762_CR33","first-page":"1353","volume":"37","author":"A Pourmand","year":"2019","unstructured":"Pourmand A, Whiteside T, Yamane D, Rashed A, Mazer-Amirshahi M. The controversial role of corticosteroids in septic shock. Am J Emerg Med. 2019;37(7):1353\u201361.","journal-title":"Am J Emerg Med"},{"issue":"11","key":"4762_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247.","journal-title":"Intensive Care Med"},{"issue":"8","key":"4762_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"13","key":"4762_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317\u201329.","journal-title":"JAMA"},{"issue":"1","key":"4762_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13054-022-04185-9","volume":"26","author":"MS Winkler","year":"2022","unstructured":"Winkler MS, Osuchowski MF, Payen D, Torres A, Dickel S, Skirecki T. Renaissance of glucocorticoids in critical care in the era of COVID-19: ten urging questions. Crit Care. 2022;26(1):308.","journal-title":"Crit Care"},{"issue":"1","key":"4762_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-023-04561-z","volume":"27","author":"JY Wu","year":"2023","unstructured":"Wu JY, Tsai YW, Hsu WH, Liu TH, Huang PY, Chuang MH, et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):274.","journal-title":"Crit Care"},{"issue":"21","key":"4762_CR39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"PF Dequin","year":"2023","unstructured":"Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931\u201341.","journal-title":"N Engl J Med"},{"issue":"13","key":"4762_CR40","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.11825","volume":"322","author":"AA Fowler","year":"2019","unstructured":"Fowler AA, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261\u201370.","journal-title":"JAMA"},{"issue":"5","key":"4762_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2019.22176","volume":"323","author":"T Fujii","year":"2020","unstructured":"Fujii T, Luethi N, Young PJ, Frei DR, Eastwood GM, French CJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA. 2020;323(5):423\u201331.","journal-title":"JAMA"},{"issue":"25","key":"4762_CR42","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa2200644","volume":"386","author":"F Lamontagne","year":"2022","unstructured":"Lamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022;386(25):2387\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"4762_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13054-023-04392-y","volume":"27","author":"B Liang","year":"2023","unstructured":"Liang B, Su J, Shao H, Chen H, Xie B. The outcome of IV vitamin C therapy in patients with sepsis or septic shock: a meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):109.","journal-title":"Crit Care"},{"issue":"12","key":"4762_CR44","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/CCM.0000000000005263","volume":"49","author":"R Sato","year":"2021","unstructured":"Sato R, Hasegawa D, Prasitlumkum N, Ueoka M, Nishida K, Takahashi K, et al. Effect of IV high-dose vitamin C on mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2021;49(12):2121\u201330.","journal-title":"Crit Care Med"},{"issue":"1","key":"4762_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13054-022-03909-1","volume":"26","author":"A Sauer","year":"2022","unstructured":"Sauer A, Putensen C, Bode C. Immunomodulation by tetracyclines in the critically ill: an emerging treatment option? Crit Care. 2022;26(1):74.","journal-title":"Crit Care"},{"key":"4762_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1164\/rccm.202005-1916OC","volume":"204","author":"K Peukert","year":"2021","unstructured":"Peukert K, Fox M, Schulz S, Feuerborn C, Frede S, Putensen C, et al. Inhibition of caspase-1 with tetracycline ameliorates acute lung injury. Am J Respir Crit Care Med. 2021;204:53\u201363.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4762_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.intimp.2013.10.025","volume":"18","author":"C Bode","year":"2014","unstructured":"Bode C, Diedrich B, Muenster S, Hentschel V, Weisheit C, Rommelsheim K, et al. Antibiotics regulate the immune response in both presence and absence of lipopolysaccharide through modulation of Toll-like receptors, cytokine production and phagocytosis in vitro. Int Immunopharmacol. 2014;18(1):27\u201334.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4762_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.immuni.2020.09.011","volume":"54","author":"HG Cola\u00e7o","year":"2021","unstructured":"Cola\u00e7o HG, Barros A, Neves-Costa A, Seixas E, Pedroso D, Velho T, et al. Tetracycline antibiotics induce host-dependent disease tolerance to infection. Immunity. 2021;54(1):53-67.e7.","journal-title":"Immunity"},{"issue":"1","key":"4762_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1574891X10666150410153839","volume":"10","author":"TM Fredeking","year":"2015","unstructured":"Fredeking TM, Zavala-Castro JE, Gonz\u00e1lez-Mart\u00ednez P, Moguel-Rodr\u00edguez W, Sanchez EC, Foster MJ, et al. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Anti-Infect Drug Discov. 2015;10(1):51\u20138.","journal-title":"Recent Pat Anti-Infect Drug Discov"},{"issue":"162","key":"4762_CR50","doi-asserted-by":"publisher","first-page":"210093","DOI":"10.1183\/16000617.0093-2021","volume":"30","author":"A Sauer","year":"2021","unstructured":"Sauer A, Peukert K, Putensen C, Bode C. Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment. Eur Respir Rev. 2021;30(162):210093.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"4762_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13054-022-04055-4","volume":"26","author":"E Karakike","year":"2022","unstructured":"Karakike E, Scicluna BP, Roumpoutsou M, Mitrou I, Karampela N, Karageorgos A, et al. Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Crit Care. 2022;26(1):183.","journal-title":"Crit Care"},{"issue":"1","key":"4762_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34\u201345.","journal-title":"Nat Rev Immunol"},{"key":"4762_CR53","doi-asserted-by":"publisher","first-page":"1144229","DOI":"10.3389\/fimmu.2023.1144229","volume":"14","author":"E Maneta","year":"2023","unstructured":"Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K, et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol. 2023;14:1144229.","journal-title":"Front Immunol"},{"issue":"22","key":"4762_CR54","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055\u201364.","journal-title":"N Engl J Med"},{"issue":"5","key":"4762_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11908-013-0358-9","volume":"15","author":"PS Lai","year":"2013","unstructured":"Lai PS, Thompson BT. Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills? Curr Infect Dis Rep. 2013;15(5):407\u201312.","journal-title":"Curr Infect Dis Rep"},{"issue":"10","key":"4762_CR56","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699\u2013709.","journal-title":"N Engl J Med"},{"issue":"1","key":"4762_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13054-019-2552-0","volume":"23","author":"T Ito","year":"2019","unstructured":"Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23(1):280.","journal-title":"Crit Care"},{"issue":"20","key":"4762_CR58","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2019.5358","volume":"321","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321(20):1993\u20132002.","journal-title":"JAMA"},{"issue":"9","key":"4762_CR59","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/CCM.0b013e31828e9b03","volume":"41","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069\u201379.","journal-title":"Crit Care Med"},{"issue":"12","key":"4762_CR60","doi-asserted-by":"publisher","first-page":"e012850","DOI":"10.1136\/bmjopen-2016-012850","volume":"6","author":"A Hagiwara","year":"2016","unstructured":"Hagiwara A, Tanaka N, Uemura T, Matsuda W, Kimura A. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial. BMJ Open. 2016;6(12):e012850.","journal-title":"BMJ Open"},{"issue":"7","key":"4762_CR61","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jth.14812","volume":"18","author":"E Valeriani","year":"2020","unstructured":"Valeriani E, Squizzato A, Gallo A, Porreca E, Vincent JL, Iba T, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(7):1618\u201325.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"4762_CR62","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2002-06-1887","volume":"101","author":"WC Aird","year":"2003","unstructured":"Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101(10):3765\u201377.","journal-title":"Blood"},{"issue":"11","key":"4762_CR63","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","volume":"47","author":"PF Laterre","year":"2021","unstructured":"Laterre PF, Pickkers P, Marx G, Wittebole X, Meziani F, Dugernier T, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021;47(11):1284\u201394.","journal-title":"Intensive Care Med"},{"key":"4762_CR64","doi-asserted-by":"publisher","first-page":"1058235","DOI":"10.3389\/fmed.2022.1058235","volume":"9","author":"D van Lier","year":"2022","unstructured":"van Lier D, Picod A, Marx G, Laterre PF, Hartmann O, Knothe C, et al. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial. Front Med (Lausanne). 2022;9:1058235.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"4762_CR65","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s00134-021-06512-0","volume":"47","author":"PD Wendel Garcia","year":"2021","unstructured":"Wendel Garcia PD, Hilty MP, Held U, Kleinert EM, Maggiorini M. Cytokine adsorption in severe, refractory septic shock. Intensive Care Med. 2021;47(11):1334\u20136.","journal-title":"Intensive Care Med"},{"issue":"11","key":"4762_CR66","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","volume":"47","author":"E Garbero","year":"2021","unstructured":"Garbero E, Livigni S, Ferrari F, Finazzi S, Langer M, Malacarne P, et al. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. 2021;47(11):1303\u201311.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4762_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13054-023-04492-9","volume":"27","author":"S Becker","year":"2023","unstructured":"Becker S, Lang H, Vollmer Barbosa C, Tian Z, Melk A, Schmidt BMW. Efficacy of CytoSorb\u00ae: a systematic review and meta-analysis. Crit Care. 2023;27(1):215.","journal-title":"Crit Care"},{"issue":"1","key":"4762_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13054-022-04003-2","volume":"26","author":"K Stahl","year":"2022","unstructured":"Stahl K, Wand P, Seeliger B, Wendel-Garcia PD, Schmidt JJ, Schmidt BMW, et al. Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022;26(1):134.","journal-title":"Crit Care"},{"issue":"1","key":"4762_CR69","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s13054-020-03241-6","volume":"24","author":"PD Keith","year":"2020","unstructured":"Keith PD, Wells AH, Hodges J, Fast SH, Adams A, Scott LK. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience. Crit Care. 2020;24(1):518.","journal-title":"Crit Care"},{"issue":"3","key":"4762_CR70","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00134-020-06339-1","volume":"47","author":"S David","year":"2021","unstructured":"David S, Bode C, Putensen C, Welte T, Stahl K, EXCHANGE Study Group. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med. 2021;47(3):352\u20134.","journal-title":"Intensive Care Med"},{"key":"4762_CR71","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.mbplus.2021.100095","volume":"12","author":"T Pape","year":"2021","unstructured":"Pape T, Hunkem\u00f6ller AM, K\u00fcmpers P, Haller H, David S, Stahl K. Targeting the \u201csweet spot\u201d in septic shock: a perspective on the endothelial glycocalyx regulating proteins Heparanase-1 and -2. Matrix Biol Plus. 2021;12:100095.","journal-title":"Matrix Biol Plus"},{"issue":"1","key":"4762_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40635-021-00417-4","volume":"9","author":"K Stahl","year":"2021","unstructured":"Stahl K, Hillebrand UC, Kiyan Y, Seeliger B, Schmidt JJ, Schenk H, et al. Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Med Exp. 2021;9(1):57.","journal-title":"Intensive Care Med Exp"},{"issue":"7","key":"4762_CR73","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/08850666231170775","volume":"38","author":"OPE Lee","year":"2023","unstructured":"Lee OPE, Kanesan N, Leow EH, Sultana R, Chor YK, Gan CS, et al. Survival benefits of therapeutic plasma exchange in severe sepsis and septic shock: a systematic review and meta-analysis. J Intensive Care Med. 2023;38(7):598\u2013611.","journal-title":"J Intensive Care Med"},{"issue":"6","key":"4762_CR74","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s13054-014-0699-2","volume":"18","author":"E Rimmer","year":"2014","unstructured":"Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18(6):699.","journal-title":"Crit Care"},{"issue":"4","key":"4762_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00134-003-1666-6","volume":"29","author":"A Nierhaus","year":"2003","unstructured":"Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med. 2003;29(4):646\u201351.","journal-title":"Intensive Care Med"},{"issue":"7","key":"4762_CR76","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4762_CR77","doi-asserted-by":"publisher","first-page":"R58","DOI":"10.1186\/cc10031","volume":"15","author":"L Bo","year":"2011","unstructured":"Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15(1):R58.","journal-title":"Crit Care"},{"issue":"78","key":"4762_CR78","doi-asserted-by":"publisher","first-page":"154330","DOI":"10.1016\/j.jcrc.2023.154330","volume":"31","author":"CH Vacheron","year":"2023","unstructured":"Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: the GRID randomized controlled trial. J Crit Care. 2023;31(78):154330.","journal-title":"J Crit Care"},{"key":"4762_CR79","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","volume":"43","author":"JD Burke","year":"2019","unstructured":"Burke JD, Young HA. IFN-\u03b3: a cytokine at the right time, is in the right place. Semin Immunol. 2019;43:101280.","journal-title":"Semin Immunol"},{"issue":"6","key":"4762_CR80","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm0697-678","volume":"3","author":"WD D\u00f6cke","year":"1997","unstructured":"D\u00f6cke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678\u201381.","journal-title":"Nat Med"},{"issue":"1","key":"4762_CR81","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","volume":"19","author":"D Payen","year":"2019","unstructured":"Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissi\u00e8res P, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019;19(1):931.","journal-title":"BMC Infect Dis"},{"key":"4762_CR82","doi-asserted-by":"publisher","first-page":"753849","DOI":"10.3389\/fimmu.2021.753849","volume":"12","author":"C Grimm","year":"2021","unstructured":"Grimm C, Dickel S, Grundmann J, Payen D, Schanz J, Zautner AE, et al. Case report: interferon-\u03b3 rescues monocytic human leukocyte antigen receptor (mHLA-DR) function in a COVID-19 patient with ARDS and superinfection with multiple MDR 4MRGN bacterial strains. Front Immunol. 2021;12:753849.","journal-title":"Front Immunol"},{"issue":"14","key":"4762_CR83","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","volume":"26","author":"CE Delsing","year":"2014","unstructured":"Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;26(14):166.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"4762_CR84","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.xcrm.2022.100817","volume":"3","author":"K Leventogiannis","year":"2022","unstructured":"Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817.","journal-title":"Cell Rep Med"},{"issue":"12","key":"4762_CR85","doi-asserted-by":"publisher","first-page":"e067251","DOI":"10.1136\/bmjopen-2022-067251","volume":"12","author":"A Kotsaki","year":"2022","unstructured":"Kotsaki A, Pickkers P, Bauer M, Calandra T, Lupse M, Wiersinga WJ, et al. ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open. 2022;12(12):e067251.","journal-title":"BMJ Open"},{"issue":"6","key":"4762_CR86","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1172\/JCI128075","volume":"130","author":"EY Kim","year":"2020","unstructured":"Kim EY, Ner-Gaon H, Varon J, Cullen AM, Guo J, Choi J, et al. Post-sepsis immunosuppression depends on NKT cell regulation of mTOR\/IFN-\u03b3 in NK cells. J Clin Invest. 2020;130(6):3238\u201352.","journal-title":"J Clin Invest"},{"issue":"5","key":"4762_CR87","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00134-023-07065-0","volume":"49","author":"A Roquilly","year":"2023","unstructured":"Roquilly A, Francois B, Huet O, Launey Y, Lasocki S, Weiss E, et al. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Med. 2023;49(5):530\u201344.","journal-title":"Intensive Care Med"},{"issue":"5","key":"4762_CR88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5501\/wjv.v9.i5.67","volume":"9","author":"A Dominari","year":"2020","unstructured":"Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67\u201378.","journal-title":"World J Virol"},{"issue":"1","key":"4762_CR89","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/cc11932","volume":"17","author":"J Wu","year":"2013","unstructured":"Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8.","journal-title":"Crit Care"},{"key":"4762_CR90","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2014.12.032","volume":"33","author":"C Li","year":"2015","unstructured":"Li C, Bo L, Liu Q, Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015;33:90\u20136.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"4762_CR91","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jcrc.2012.08.004","volume":"27","author":"E Tamayo","year":"2012","unstructured":"Tamayo E, Fern\u00e1ndez A, Almansa R, Carrasco E, Goncalves L, Heredia M, et al. Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care. 2012;27(6):616\u201322.","journal-title":"J Crit Care"},{"issue":"4","key":"4762_CR92","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/joim.12265","volume":"276","author":"JF Bermejo-Mart\u00edn","year":"2014","unstructured":"Bermejo-Mart\u00edn JF, Rodriguez-Fernandez A, Herr\u00e1n-Monge R, Andaluz-Ojeda D, Muriel-Bomb\u00edn A, Merino P, et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med. 2014;276(4):404\u201312.","journal-title":"J Intern Med"},{"issue":"5","key":"4762_CR93","first-page":"559","volume":"82","author":"S Busani","year":"2016","unstructured":"Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol. 2016;82(5):559\u201372.","journal-title":"Minerva Anestesiol"},{"issue":"1","key":"4762_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13613-019-0501-3","volume":"9","author":"J Cui","year":"2019","unstructured":"Cui J, Wei X, Lv H, Li Y, Li P, Chen Z, et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019;9(1):27.","journal-title":"Ann Intensive Care"},{"issue":"3","key":"4762_CR95","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17476348.2021.1848555","volume":"15","author":"E Gorman","year":"2021","unstructured":"Gorman E, Millar J, McAuley D, O\u2019Kane C. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. Expert Rev Respir Med. 2021;15(3):301\u201324.","journal-title":"Expert Rev Respir Med"},{"issue":"7","key":"4762_CR96","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/CCM.0000000000003657","volume":"47","author":"K Schlosser","year":"2019","unstructured":"Schlosser K, Wang JP, Dos Santos C, Walley KR, Marshall J, Fergusson DA, et al. Effects of mesenchymal stem cell treatment on systemic cytokine levels in a phase 1 dose escalation safety trial of septic shock patients. Crit Care Med. 2019;47(7):918\u201325.","journal-title":"Crit Care Med"},{"issue":"8","key":"4762_CR97","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.5966\/sctm.2015-0138","volume":"5","author":"JM C\u00f3ndor","year":"2016","unstructured":"C\u00f3ndor JM, Rodrigues CE, de Sousa Moreira R, Canale D, Volpini RA, Shimizu MHM, et al. Treatment with human Wharton\u2019s jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction. Stem Cells Transl Med. 2016;5(8):1048\u201357.","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"4762_CR98","doi-asserted-by":"publisher","first-page":"L1003","DOI":"10.1152\/ajplung.00180.2011","volume":"302","author":"A Krasnodembskaya","year":"2012","unstructured":"Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1003-1013.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"4762_CR99","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13287-020-01730-7","volume":"11","author":"XY Sun","year":"2020","unstructured":"Sun XY, Ding XF, Liang HY, Zhang XJ, Liu SH, Bing-Han, et al. Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies. Stem Cell Res Ther. 2020;11(1):214.","journal-title":"Stem Cell Res Ther"},{"key":"4762_CR100","doi-asserted-by":"publisher","first-page":"792098","DOI":"10.3389\/fimmu.2021.792098","volume":"12","author":"L Ge","year":"2021","unstructured":"Ge L, Zhao J, Deng H, Chen C, Hu Z, Zeng L. Effect of bone marrow mesenchymal stromal cell therapies in rodent models of sepsis: a meta-analysis. Front Immunol. 2021;12:792098.","journal-title":"Front Immunol"},{"issue":"3","key":"4762_CR101","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1164\/rccm.201705-1006OC","volume":"197","author":"LA McIntyre","year":"2018","unstructured":"McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, et al. Cellular immunotherapy for septic shock. A phase I clinical trial. Am J Respir Crit Care Med. 2018;197(3):337\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"4762_CR102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trsl.2018.04.006","volume":"199","author":"X He","year":"2018","unstructured":"He X, Ai S, Guo W, Yang Y, Wang Z, Jiang D, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. Transl Res. 2018;199:52\u201361.","journal-title":"Transl Res"},{"issue":"1","key":"4762_CR103","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13054-022-03930-4","volume":"26","author":"A Monsel","year":"2022","unstructured":"Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022;26(1):48.","journal-title":"Crit Care"},{"key":"4762_CR104","doi-asserted-by":"publisher","first-page":"624272","DOI":"10.3389\/fimmu.2020.624272","volume":"11","author":"MA McBride","year":"2020","unstructured":"McBride MA, Patil TK, Bohannon JK, Hernandez A, Sherwood ER, Patil NK. Immune checkpoints: novel therapeutic targets to attenuate sepsis-induced immunosuppression. Front Immunol. 2020;11:624272.","journal-title":"Front Immunol"},{"issue":"23","key":"4762_CR105","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","volume":"306","author":"JS Boomer","year":"2011","unstructured":"Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594\u2013605.","journal-title":"JAMA"},{"issue":"6","key":"4762_CR106","doi-asserted-by":"publisher","first-page":"R276","DOI":"10.1186\/cc13131","volume":"17","author":"NJ Shubin","year":"2013","unstructured":"Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A. B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care. 2013;17(6):R276.","journal-title":"Crit Care"},{"issue":"2","key":"4762_CR107","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/cc10112","volume":"15","author":"C Guignant","year":"2011","unstructured":"Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011;15(2):R99.","journal-title":"Crit Care"},{"issue":"6","key":"4762_CR108","doi-asserted-by":"publisher","first-page":"R220","DOI":"10.1186\/cc9354","volume":"14","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.","journal-title":"Crit Care"},{"issue":"2","key":"4762_CR109","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1189\/jlb.0110037","volume":"88","author":"P Brahmamdam","year":"2010","unstructured":"Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233\u201340.","journal-title":"J Leukoc Biol"},{"issue":"6","key":"4762_CR110","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SHK.0000000000001682","volume":"55","author":"TW Phares","year":"2021","unstructured":"Phares TW, Kotraiah V, Chung CS, Unsinger J, Mazer M, Remy KE, et al. A peptide-based checkpoint immunomodulator alleviates immune dysfunction in murine polymicrobial sepsis. Shock. 2021;55(6):806\u201315.","journal-title":"Shock"},{"issue":"1","key":"4762_CR111","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/cc13176","volume":"18","author":"K Chang","year":"2014","unstructured":"Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18(1):R3.","journal-title":"Crit Care"},{"issue":"6","key":"4762_CR112","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1189\/jlb.4HI0616-255R","volume":"100","author":"AC Patera","year":"2016","unstructured":"Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS. Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016;100(6):1239\u201354.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"4762_CR113","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","volume":"17","author":"D Grimaldi","year":"2017","unstructured":"Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4762_CR114","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SHK.0000000000001443","volume":"53","author":"E Watanabe","year":"2020","unstructured":"Watanabe E, Nishida O, Kakihana Y, Odani M, Okamura T, Harada T, et al. Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study. Shock. 2020;53(6):686\u201394.","journal-title":"Shock"},{"issue":"10","key":"4762_CR115","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","volume":"45","author":"RS Hotchkiss","year":"2019","unstructured":"Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45(10):1360\u201371.","journal-title":"Intensive Care Med"},{"issue":"20","key":"4762_CR116","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CCH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317.","journal-title":"JAMA"},{"issue":"1","key":"4762_CR117","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13054-021-03541-5","volume":"25","author":"D Kudo","year":"2021","unstructured":"Kudo D, Goto T, Uchimido R, Hayakawa M, Yamakawa K, Abe T, et al. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies. Crit Care. 2021;25(1):114.","journal-title":"Crit Care"},{"issue":"1","key":"4762_CR118","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13054-018-2279-3","volume":"22","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Zhang G, Goyal H, Mo L, Hong Y. Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis. Crit Care. 2018;22(1):347.","journal-title":"Crit Care"},{"issue":"10","key":"4762_CR119","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1097\/CCM.0000000000005054","volume":"49","author":"X Han","year":"2021","unstructured":"Han X, Spicer A, Carey KA, Gilbert ER, Laiteerapong N, Shah NS, et al. Identifying high-risk subphenotypes and associated harms from delayed antibiotic orders and delivery. Crit Care Med. 2021;49(10):1694\u2013705.","journal-title":"Crit Care Med"},{"issue":"3","key":"4762_CR120","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1164\/rccm.201806-1197OC","volume":"200","author":"SV Bhavani","year":"2019","unstructured":"Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019;200(3):327\u201335.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"4762_CR121","doi-asserted-by":"publisher","first-page":"e58142","DOI":"10.7554\/eLife.58142","volume":"22","author":"R Liu","year":"2020","unstructured":"Liu R, Greenstein JL, Fackler JC, Bembea MM, Winslow RL. Spectral clustering of risk score trajectories stratifies sepsis patients by clinical outcome and interventions received. Elife. 2020;22(9):e58142.","journal-title":"Elife"},{"issue":"5","key":"4762_CR122","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00134-019-05596-z","volume":"45","author":"G Geri","year":"2019","unstructured":"Geri G, Vignon P, Aubry A, Fedou AL, Charron C, Silva S, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a post hoc analysis. Intensive Care Med. 2019;45(5):657\u201367.","journal-title":"Intensive Care Med"},{"issue":"7","key":"4762_CR123","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1741-7015-7-34","volume":"22","author":"HR Wong","year":"2009","unstructured":"Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009;22(7):34.","journal-title":"BMC Med"},{"issue":"10","key":"4762_CR124","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1097\/CCM.0b013e3181eb924f","volume":"38","author":"HR Wong","year":"2010","unstructured":"Wong HR, Wheeler DS, Tegtmeyer K, Poynter SE, Kaplan JM, Chima RS, et al. Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med. 2010;38(10):1955\u201361.","journal-title":"Crit Care Med"},{"issue":"3","key":"4762_CR125","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1164\/rccm.201410-1864OC","volume":"191","author":"HR Wong","year":"2015","unstructured":"Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309\u201315.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4762_CR126","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","volume":"4","author":"EE Davenport","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259\u201371.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"4762_CR127","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"4762_CR128","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","volume":"5","author":"BP Scicluna","year":"2017","unstructured":"Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5(10):816\u201326.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"4762_CR129","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/CCM.0000000000003084","volume":"46","author":"TE Sweeney","year":"2018","unstructured":"Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018;46(6):915\u201325.","journal-title":"Crit Care Med"},{"issue":"1","key":"4762_CR130","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13054-020-2830-x","volume":"24","author":"GP Leijte","year":"2020","unstructured":"Leijte GP, Rimmel\u00e9 T, Kox M, Bruse N, Monard C, Gossez M, et al. Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes. Crit Care. 2020;24(1):110.","journal-title":"Crit Care"},{"issue":"2","key":"4762_CR131","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1097\/SLA.0000000000003974","volume":"275","author":"LPA Neyton","year":"2022","unstructured":"Neyton LPA, Zheng X, Skouras C, Doeschl-Wilson A, Gutmann MU, Uings I, et al. Molecular patterns in acute pancreatitis reflect generalizable endotypes of the host response to systemic injury in humans. Ann Surg. 2022;275(2):e453\u201362.","journal-title":"Ann Surg"},{"issue":"7862","key":"4762_CR132","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-021-03583-3","volume":"594","author":"S Warnat-Herresthal","year":"2021","unstructured":"Warnat-Herresthal S, Schultze H, Shastry KL, Manamohan S, Mukherjee S, Garg V, et al. Swarm learning for decentralized and confidential clinical machine learning. Nature. 2021;594(7862):265\u201370.","journal-title":"Nature"},{"issue":"1","key":"4762_CR133","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13054-023-04374-0","volume":"27","author":"AR Schuurman","year":"2023","unstructured":"Schuurman AR, Sloot PMA, Wiersinga WJ, van der Poll T. Embracing complexity in sepsis. Crit Care. 2023;27(1):102.","journal-title":"Crit Care"},{"issue":"5","key":"4762_CR134","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201211-1983OC","volume":"187","author":"O Takasu","year":"2013","unstructured":"Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013;187(5):509\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4762_CR135","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccm.2008.06.003","volume":"29","author":"M Singer","year":"2008","unstructured":"Singer M. Cellular dysfunction in sepsis. Clin Chest Med. 2008;29(4):655\u201360.","journal-title":"Clin Chest Med"},{"issue":"10","key":"4762_CR136","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.it.2014.08.001","volume":"35","author":"MP Soares","year":"2014","unstructured":"Soares MP, Gozzelino R, Weis S. Tissue damage control in disease tolerance. Trends Immunol. 2014;35(10):483\u201394.","journal-title":"Trends Immunol"},{"issue":"6071","key":"4762_CR137","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.1214935","volume":"335","author":"R Medzhitov","year":"2012","unstructured":"Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335(6071):936\u201341.","journal-title":"Science"},{"issue":"195","key":"4762_CR138","doi-asserted-by":"publisher","first-page":"195ra95","DOI":"10.1126\/scitranslmed.3005893","volume":"5","author":"RJ Langley","year":"2013","unstructured":"Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013;5(195):195ra95.","journal-title":"Sci Transl Med"},{"issue":"5","key":"4762_CR139","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.immuni.2013.08.039","volume":"39","author":"N Figueiredo","year":"2013","unstructured":"Figueiredo N, Chora A, Raquel H, Pejanovic N, Pereira P, Hartleben B, et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity. 2013;39(5):874\u201384.","journal-title":"Immunity"},{"issue":"9","key":"4762_CR140","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.cmet.2021.07.002","volume":"33","author":"J Vandewalle","year":"2021","unstructured":"Vandewalle J, Timmermans S, Paakinaho V, Vancraeynest L, Dewyse L, Vanderhaeghen T, et al. Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis. Cell Metab. 2021;33(9):1763-1776.e5.","journal-title":"Cell Metab"},{"issue":"7","key":"4762_CR141","doi-asserted-by":"publisher","first-page":"e0286525","DOI":"10.1371\/journal.pone.0286525","volume":"18","author":"BP Leitner","year":"2023","unstructured":"Leitner BP, Lee WD, Zhu W, Zhang X, Gaspar RC, Li Z, et al. Tissue-specific reprogramming of glutamine metabolism maintains tolerance to sepsis. PLoS ONE. 2023;18(7):e0286525.","journal-title":"PLoS ONE"},{"issue":"6","key":"4762_CR142","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/JLB.3MR0322-692RR","volume":"112","author":"CE McCall","year":"2022","unstructured":"McCall CE, Zhu X, Zabalawi M, Long D, Quinn MA, Yoza BK, et al. Sepsis, pyruvate, and mitochondria energy supply chain shortage. J Leukoc Biol. 2022;112(6):1509\u201314.","journal-title":"J Leukoc Biol"},{"issue":"7928","key":"4762_CR143","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41586-022-05128-8","volume":"609","author":"F Karagiannis","year":"2022","unstructured":"Karagiannis F, Peukert K, Surace L, Michla M, Nikolka F, Fox M, et al. Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature. 2022;609(7928):801\u20137.","journal-title":"Nature"},{"key":"4762_CR144","doi-asserted-by":"publisher","unstructured":"Powell RE, Soares MP, Weis S. What\u2019s new in intensive care: disease tolerance. Intensive Care Med. 2023;49(10):1235\u20131237. https:\/\/doi.org\/10.1007\/s00134-023-07130-8.","DOI":"10.1007\/s00134-023-07130-8"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04762-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T05:08:15Z","timestamp":1701839295000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4762"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04762-6","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"478"}}